|
BRPI0800989A2
|
|
me- inhibitors formed by n- (arylamino) sulfonamide
|
|
US2009029983A1
|
|
Novel heterocyclic compounds having anti-hbv activity
|
|
WO2007014023A1
|
|
Thiazolidinones, oxazolidinones, and pyrrolidinones for hbv
|
|
WO2007027248A2
|
|
3', 5' - cyclic nucleoside analogues for treatment of hcv
|
|
WO2006122207A1
|
|
6-hydrazinopurine 2'-methyl ribonucleosides and nucleotides for treatment of hcv
|
|
WO2006127289A1
|
|
Treatment of hcv with subtherapeutic doses of ribavirin
|
|
WO2006121820A1
|
|
Phosphoramidate prodrugs for treatment of viral infection
|
|
WO2007050087A1
|
|
N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
|
|
WO2006005017A2
|
|
Oral composition comprising carbamylating agent
|
|
US2005009766A1
|
|
Use of ribofuranose derivatives against inflammatory bowel diseases
|
|
US6989451B2
|
|
Heterocyclic compounds and uses thereof
|
|
US7247621B2
|
|
Antiviral phosphonate compounds and methods therefor
|
|
US2006205026A1
|
|
Parallel inducible cell-based kinase screen
|
|
US2006135768A1
|
|
Synthesis for hydroxyalkylated heterocyclic bases
|
